Show simple item record

dc.contributor.authorOlive, Colleen
dc.contributor.authorSun, Hsien Kuo
dc.contributor.authorHo, Mei-Fong
dc.contributor.authorDyer, Joanne
dc.contributor.authorHorváth, Aniko
dc.contributor.authorToth, Istvan
dc.contributor.authorF. Good, Michael
dc.date.accessioned2017-05-03T14:54:04Z
dc.date.available2017-05-03T14:54:04Z
dc.date.issued2006
dc.date.modified2014-05-22T22:15:20Z
dc.identifier.issn00221899
dc.identifier.doi10.1086/505580
dc.identifier.urihttp://hdl.handle.net/10072/59201
dc.description.abstractBackground We investigated the lipid core peptide (LCP) system for mucosal vaccine delivery against infection with group A streptococcus (GAS)-the causative pathogen of rheumatic fever and rheumatic heart disease Methods An LCP vaccine formulation containing 2 different peptide epitopes of the antiphagocytic M protein of GAS-a conformational epitope from the carboxyterminal conserved C-repeat region and an aminoterminal serotypic epitope-was intranasally administered to mice with cholera toxin B subunit or without additional adjuvant Results Our data demonstrate that the LCP vaccine formulation induced the elicitation of antigen-specific systemic immunoglobulin G responses when administered with or without cholera toxin B subunit, whereas cholera toxin B subunit was required for the induction of antigen-specific mucosal immunoglobulin A responses. Immune serum samples from vaccinated mice were capable of opsonization of a homologous GAS strain, as well as opsonization of a heterologous GAS strain. Furthermore, mice were protected from GAS challenge following immunization with the LCP vaccine formulation, even in the absence of additional adjuvant Conclusions These data support the potential of the LCP system in the development of a self-adjuvanting, synthetic, peptide-based mucosal GAS vaccine for the prevention of diseases caused by GAS
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherOxford University Press
dc.publisher.placeUnited States
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom316
dc.relation.ispartofpageto324
dc.relation.ispartofissue3
dc.relation.ispartofjournalJournal of Infectious Diseases
dc.relation.ispartofvolume194
dc.rights.retentionY
dc.subject.fieldofresearchMedical Microbiology not elsewhere classified
dc.subject.fieldofresearchBiological Sciences
dc.subject.fieldofresearchMedical and Health Sciences
dc.subject.fieldofresearchcode110899
dc.subject.fieldofresearchcode06
dc.subject.fieldofresearchcode11
dc.titleIntranasal Administration Is an Effective Mucosal Vaccine Delivery Route for Self-Adjuvanting Lipid Core Peptides Targeting the Group A Streptococcal M Protein
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorGood, Michael F.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record